北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月27日，康恩贝发布公告称，2025年上半年实现营业收 入33.58亿元，同比下降2.61%；归属于上市公司股东的净利润为3.54亿元，同比下降7.48%；归属于上 市公司股东的扣除非经常性损益的净利润为2.97亿元，同比下降11.86%。 ...

| 证券代码：600572 证券简称：康恩贝 公告编号：临 | | | 2025-044 | | | | --- | --- | --- | --- | --- | --- | | 浙江康恩贝制药股份有限公司 | | | | | | | 关于持股 5%以上股东权益变动触及 1%刻度的 | | | | | | | 提示性公告 | | | | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， | | | | | | | 并对其内容的真实性、准确性和完整性承担法律责任。 | | | | | | | 重要内容提示： | | | | | | | 权益变动方向 比例增加□ 比例减少 | | | | | | | 权益变动前合计比例 14.143% | | | | | | | 13.944% 权益变动后合计比例 | | | | | | | 本次变动是否违反已作出的承诺、意向、计划 是□ | 否 | | | | | | 是否触发强制要约收购义务 是□ 否 | | | | | | | 一、信息披露义务人及其一致行动人的基本信息 | | | | | | | （一）身份类别 | | | | ...

浙江康恩贝制药股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600572 证券简称：康恩贝 公告编号：临 2025-044 重要内容提示： | 权益变动方向 | 比例增加□ | 比例减少☑ | | --- | --- | --- | | 权益变动前合计比例 | 14.143% | | | 权益变动后合计比例 | 13.944% | | | 本次变动是否违反已作出的承诺、意向、计划 | 是□ | 否☑ | | 是否触发强制要约收购义务 | 是□ | 否☑ | 一、信息披露义务人及其一致行动人的基本信息 （一）身份类别 □控股股东/实际控制人及其一致行动人 ☑其他 5%以上大股东及其一致行动人 □合并口径第一大股东及其一致行动人（仅适用于无控股 股东、实际控制人） □其他 投资者及其一致行动人的身份 （二）信息披露义务人信息 | 信息披露义务人名称 | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | | | □控股股 ...

| 交易日期 | 证券简称 | 证券代码 | | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2025-08-27 | 康恩贝 | 600572 | 2230 4.46 | 500 | 中国银河证券股份 有限公司杭州建国 | 中信证券股份有限 公司杭州庆春路证 | | | | | | | 4100 T *** 11 | *** = | 8月27日，康恩贝大宗交易成交500万股，成交额2230万元，占当日总成交额的7.54%，成交价4.46元，较市场收盘价4.55元折价1.98%。 ...

证券代码：600572 证券简称：康恩贝 公告编号：临 2025-043 浙江康恩贝制药股份有限公司 关于公司 2025 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 浙江康恩贝制药股份有限公司（以下简称"公司"）根据上海证券交易所发布 的上市公司分行业信息披露指引《上市公司行业信息披露指引第六号——医药制造》 及《关于做好上市公司 2025 年半年度报告披露工作的通知》相关要求，现将公司 2025 年半年度主要经营数据披露如下： 一、报告期内分行业经营数据 | 分治疗 | 营业收入 | 营业成本 | 毛利率 | 营业收入 比上年增 | 营业成本比 上年增减 | 毛利率比上 | | --- | --- | --- | --- | --- | --- | --- | | 领域 | | | (%) | 减（%） | （%） | 年增减（%） | | 心血管系统 | 26,962.58 | 9,145.83 | 66.08 | -6.15 | -0.53 | 减少1.92个百 分点 | | 生殖泌尿系统 ...

Group 1 - The company announced that its operating revenue for the first half of 2025 was 3.358 billion yuan, representing a year-on-year decrease of 2.61% [1] - The net profit for the same period was 354 million yuan, showing a year-on-year decline of 7.48% [1]

Core Insights - The event organized by Kang En Bei in Changsha featured a giant "Peach" and a 12-meter immersive intestinal pathology simulation tunnel aimed at educating the public about the deep connections between diarrhea and enteritis [1][3] - The marketing strategy focused on providing participants with a "visualization of pathology" experience, engaging young audiences and highlighting the dangers of intestinal inflammation [3][5] - The event addressed common misconceptions among consumers regarding diarrhea treatment, emphasizing the importance of not just stopping diarrhea but also addressing underlying intestinal inflammation [5][9] Marketing Strategy - The immersive experience allowed participants to feel as if they were in a real intestinal environment, showcasing varying degrees of intestinal inflammation [3] - Kang En Bei collaborated with platforms like Meituan, JD.com, Ele.me, and Taobao to enhance public engagement through online promotions, offering limited edition golden Peach blind boxes [7] Social Impact - The event served as a successful brand promotion for Kang En Bei's intestinal medicine, while also contributing significantly to public health education and setting a new benchmark for innovative pharmaceutical marketing [9]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、股东持股的基本情况 浙江康恩贝制药股份有限公司（以下简称"公司""本公司"）持股5%以上股东康恩贝集团有限公司（以 下简称"康恩贝集团"）持有公司股份254,431,171股，占公司现总股本 2,524,267,371股（按2025年8月14 日公司总股本计，下同）的10.079%；康恩贝集团和胡季强先生合计持有本公司股份357,010,256股，占 公司现总股本的14.143%，两者为本公司持股5%以上股东及一致行动人。 2、集中竞价减持计划的主要内容 康恩贝集团拟自本公告披露之日起15个交易日后的3个月内通过集中竞价交易方式减持公司股份合计不 超过25,242,673股，拟减持比例合计不超过公司总股本的1%。减持价格根据减持时的市场价格确定。若 减持期间公司有送股、资本公积转增股本等变动事项，上述数量将进行相应调整。 预披露期间，若公司股票发生停牌情形的，实际开始减持的时间根据停牌时间相应顺延。 ...

Group 1 - The core point of the announcement is that Zhejiang Kangnbei Pharmaceutical Co., Ltd. plans to reduce the shareholding of its major shareholder, Kangnbei Group Co., Ltd., through a centralized bidding method [1][2]. - Kangnbei Group holds 254,431,171 shares, accounting for 10.079% of the total share capital of 2,524,267,371 shares as of August 14, 2025 [1]. - The planned reduction will not exceed 25,242,673 shares, which is 1% of the total share capital, and the selling price will be determined based on market conditions at the time of the sale [1][2]. Group 2 - Kangnbei Group has made commitments regarding its shareholding and will comply with relevant laws and regulations during the reduction process [3]. - The reduction plan is consistent with previous commitments made by Kangnbei Group during the company's initial public offering and other related matters [3]. - The company will ensure that the reduction plan is implemented legally and in compliance with the Shanghai Stock Exchange regulations [4].

Core Viewpoint - Multiple listed companies in the Shanghai and Shenzhen markets have announced significant developments, including legal investigations, share transfers, bankruptcy applications, and financial performance updates, which may present both opportunities and risks for investors [3]. Group 1: Legal and Regulatory Developments - Sichuan Medical Technology received a notice from the Hangzhou Public Security Bureau regarding evidence collection for a suspected fraudulent securities issuance case, currently under investigation [4]. - Kewah Holdings announced that its controlling shareholder is planning a share transfer, leading to a temporary suspension of trading to ensure fair information disclosure [5]. - Upwind New Materials reported that its customer TPI Composites filed for Chapter 11 bankruptcy protection, potentially impacting the company's receivables of approximately 4.13 million USD (about 32.37 million RMB) [6][7]. Group 2: Financial Performance Updates - Dongfang Fortune reported a 38.65% year-on-year increase in revenue to 6.856 billion RMB and a 37.27% increase in net profit to 5.567 billion RMB for the first half of 2025 [14]. - Shengyi Electronics achieved a 91% increase in revenue to 3.769 billion RMB and a staggering 452% increase in net profit to 531 million RMB, proposing a cash dividend of 3 RMB per 10 shares [15]. - Blue Shield Optoelectronics reported a revenue decline of 27.26% to 186 million RMB and a net loss of 35.071 million RMB for the first half of 2025 [16]. - Tianjin Pharmaceutical reported a slight revenue decrease of 1.91% to 4.288 billion RMB, but a 16.97% increase in net profit to 775 million RMB, proposing a cash dividend of 2.1 RMB per 10 shares [17]. Group 3: Corporate Actions and Strategic Moves - New Natural Gas announced a capital restructuring and rights issue plan to raise approximately 239 million HKD for project expenditures, without affecting shareholder equity structure [8]. - Lianhong New Science plans to absorb its wholly-owned subsidiary Lianhong Chemical to enhance management efficiency and reduce costs, with no significant impact on financial status [9]. - Dazhong Pump Industry clarified that its revenue from products directly used in data center liquid cooling is only about 1.6 million RMB, representing 0.43% of total revenue, indicating limited impact on financials [10]. - Guanshi Technology stated it does not engage in the manufacturing of electron beam lithography equipment, with its related business revenue being less than 2% of total revenue [11]. Group 4: Shareholder Actions - Shuyou Shen announced that its major shareholder plans to reduce its stake by up to 2% through various trading methods [32]. - Western Gold announced a plan to reduce its stake by up to 1% due to funding needs [33]. - Kang Enbei Group intends to reduce its stake by up to 1% through market transactions [34].